Utility of free/total prostate specific antigen (f/t PSA) ratio in diagnosis of prostate carcinoma

Disease Markers

Volumn 19, Issue 6, 2003, Pages 287-292

  Thakur, V ^a   Singh, P P ^a   Talwar, M ^a   Mukherjee, U ^a  

^a Batra Hospital India   (India)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; STREPTAVIDIN;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; BLOOD LEVEL; CALCULATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CARCINOMA; RISK ASSESSMENT; SENSITIVITY AND SENSIBILITY;

EID: 3042829791     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.1155/2004/913870     Document Type: Article

References (19)

1. W.J. Catalona, D.S. Smith, T.L. Ratliff and J.W. Roster, Detection of organ confined prostate cancer is increased through prostate specific antigen based screening, JAMA 270 (1993), 948-954.
2. T.A. Stamey, N. Yang, A.R. Hay, J.E. Mcneal, F.S. Freiha and E. Redwine, Prostate specific antigen as a serum marker for adenocarcinoma of the prostate, N Eng J Med 317 (1987), 909-916.
3. A.W. Partin, H.B. Carter, D.W. Chan, J.I. Epstein, J.E. Oesterling, R.C. Rock, J.P. Weber and P.C. Walsh, Prostate specific antigen in the staging of localized prostate cancer, influence of tumor differentiation, tumor volume and benign hyperplasia, J Urol 143 (1990), 747-752.
4. K. Jung, B. Brux, M. Lein et al., Determination of alpha- antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA, Urology 53(6) (1999), 1160-1168.
5. W.J. Catalona, Clinical utility of measurements of free and total prostate specific antigen (PSA): A review, Prostate 7 (1996), 64-69.
6. P.J. Van Cangh, P. De Nayer, R. De V Ischer, P. Sanvage, B. Tombal, F. Lortge, F.X. Wese and R. Opsomer, Free to total prostate specific antigen (PSA) ratio improves the discrimination between prostate cancer and benign prostatic hyperplasia (BPH) in the diagnostic gray zone of 1.8 to 10 ng/ml total PSA, Urology 48(6A) (1996), 67-70.
7. W.J. Catalona, A.W. Partin, J.A. Finlay, D.W. Chan, S.H.G. Rittenhouse, R.L. WolFert and D.L. Woodrum, Use of Percentage of free prostate specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/ml, Urology 54(2) (1999), 220-224.
8. T.O. Morgan, D.G. Mckod, E.J. Sleifer, G.P. Murphy and J.W. Moul, Prospective use of free prostate specific antigen to avoid repeat prostate biopsies in men with elevated total prostate specific antigen, Urology 48(6A) (1996), 76-80.
9. W.J. Catalona, D.S. Smith, T.C. Ratliff, K.M. Dodds, D.E. Soplen, J.J.J. Ynan J.A. Petros and G.L. Andriole, Measurement of prostate specific antigen in serum as a screening test for prostate cancer, N. Engl J Med 324 (1991), 1156-1161.
10. M.K. Brawer, M.P. Chetner, J. Beatle, D.M. Buchner, R.L. Vesselia and R.H. large, screening for prostatic carcinoma with prostate specific antigen, J Urol 147 (1992), 841-845.
11. A. Christensson, C.B. Laurel and H. Lilja, Enzymatic activity of prostate specific antigen and its reactions with extracellular serine protease inhibitor, Eur J Biochem 194 (1990), 755-763.
12. H. Lilja, A. Christensson, U. Dahlen, M.T. Matikainen, O. Nilsson, K. Petterson and T. Lovgen, Prostate specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin, Clin Chem 37 (1991), 1618-1625.
13. G.M. Marley, M.C. Miller, M.W. Kattan, G. Zhao, K.P. Patton, R.L. Vessella, G.L. Wright, Jr, P.F. Schellhammer and R.W. Veltri, Free and complexed prostate specific antigen serum ratios to predict probability of primary prostate cancer and benign prostatic hyperplasia, Urology 48 (1996), 16-22.
14. A. Reissigl, H. Klocker, J. Pointner, K. Fink, W. Horninger, O. Ennemoser, H. Strasser, K. Colleselli, L. Holti and G. Bartsch, Usefulness of the ratio free/total prostate specific antigen in addition to total PSA levels in prostate cancer screening, Urology 48 (1996), 62-66.
15. W.J. Catalona, D.S. Smith, R.L. Wolfert, T.J. Wang, H.G. Rittenhouse, T.L. Ratliff and R.B. Nadler, Evaluation of percentage of free serum prostate specific antigen to improve specificity of prostate cancer screening, JAMA 274 (1995), 1214-1220.
16. H. Lilja, Significance of different molecular forms of serum PSA, the free noncomplexed form of PSA versus that complexed to alpha 1-antichymotrypsin, Urol. Clin. North. Ame. 20 (1993), 681-686.
17. G. Alivizatos, C. Deliveliotis, D. Mitropoulos, G. Raptides, G. Louras, K.A. arayiannes, T. Becopoulos and A.M. Dimopoulos, Does free to total ratio of prostate specific antigen alter decision making on prostate biopsy? Urology 48(6A) (1996), 71-75.
18. A.A. Luderer, Y.T. Chen, T.F. Soriano, W. Kramp, G. Carlson, C. Cuny, T. Sharp, W. Smith, Petteway, M. Brawer and R. Thiel, Measurement of the proportion of free to total prostate specific antigen improves diagnostic performance of prostate specific antigen in the diagnostic grey zone of total prostate specific antigen, Urology 46 (1994), 187-194.
19. J.E. Oesterling, S.J. Jacobson, G.G. Klee, K. Peterson, T. Piironen, P.A. Abrahmsson, U.H. Stenman, B. Dowell, T. Lorgren and H. Lilja, Free complexed and total serum prostate specific antigen. The establishment of appropriate reference ranges for their concentrations and ratios, J Urol 159 (1995), 1090-1095.